Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2989997 | 1.00 | P2RX7 (0.32) | P2RX7HSD11B1OPRM1ROCK2ATM | |
| SCHEMBL2990417 | 0.80 | ROCK2 (0.35) | P2RX7ROCK2 | |
| SCHEMBL2990419 | 0.80 | ROCK2 (0.35) | P2RX7ROCK2 | |
| SCHEMBL2991629 | 0.79 | HSD11B1 (0.38) | P2RX7HSD11B1OPRM1L3MBTL1 | |
| SCHEMBL2993650 | 0.79 | HSD11B1 (0.38) | P2RX7HSD11B1OPRM1L3MBTL1 | |
| SCHEMBL2991864 | 0.79 | HSD11B1 (0.38) | P2RX7HSD11B1OPRM1L3MBTL1 | |
| SCHEMBL2990822 | 0.78 | HSD11B1 (0.54) | P2RX7HSD11B1OPRM1ROCK2 | |
| SCHEMBL2999509 | 0.78 | HSD11B1 (0.57) | P2RX7HSD11B1OPRM1ROCK2 | |
| SCHEMBL2208101 | 0.77 | HSD11B1 (0.41) | P2RX7HSD11B1OPRM1ROCK2 | |
| SCHEMBL474663 | 0.77 | HSD11B1 (0.41) | P2RX7HSD11B1OPRM1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184764-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2010-07-22 | — | — | US | disclosed |
| US-7713979-B2 | Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1807072-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080275043-A1 | Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275043-A1 | Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSDL2, HSD17B1 | P2RX7 3884/4885HSD11B1 1/4885OPRM1 514/4885 |
| US-20100184764-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD3B1 | P2RX7 4250/4885HSD11B1 1/4885OPRM1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.